Chronic Hepatitis ENCT02419625
The Epidemiology of Hepatitis E Virus Infection in Israel and Potential Risk Factors
A study testing questionnaires in people with Chronic Hepatitis E, run by Carmel Medical Center.
Trial summary
Hepatitis E virus is a single-stranded positive-sense RNA virus with genome of approximately 7.2kb in length. The HEV genome is capped at the 5' end followed by a small untranslated region of 27 nucleotides and polyadenalated at the 3' end preceded by another UTR of 65 nucleotides . Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Chronic Hepatitis E
- What is being tested?
- questionnaires
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- No sites listed yet
- Study dates
- Jun 2015to Apr 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with elevated liver enzymes of unknown etiology
- Patients with acute hepatitis of unknown etiology
- Patients with chronic infection with hepatitis B , D or C.
- Immunosuppressed patients: patients with solid or haemato-oncologic malignancy or patients with chronic HIV infection.
- Patients with chronic liver disease of unknown etiology
- Participants who have contacts with swines: delivery, feeding, slaughtering, treatment)
- Healthy volunteers.
Who cannot join
- Participants who do not fill the above criteria
- Participants who are not willing to sign an inform consent
- Participants younger than 18 year old
About this study
Official title: The Epidemiology of Hepatitis E Virus Infection in Israel and Potential Risk Factors, a Multicenter, Comparative, Cross-sectional Study
Hepatitis E virus is a single-stranded positive-sense RNA virus with genome of approximately 7.2kb in length. The HEV genome is capped at the 5' end followed by a small untranslated region of 27 nucleotides and polyadenalated at the 3' end preceded by another UTR of 65 nucleotides . HEV has three open reading frames: ORF1, ORF2 and ORF3 that encode structural and non- structural proteins. ORF1 is the largest one, approximately 5,000 nt in length, located at the 5 ' end and encodes important proteins for the replication process (methyltransferase, papain-like cysteine protease, helicase, and RNA-dependent RNA polymerase). A noncoding, hypervariable region within ORF1 displays substantial genetic diversity; this region seems to modulate the efficiency of HEV replication. Notably, the differences in the genome size among different HEV strains are confined mainly to this region .ORF2 is located at the 3' end, encodes structural capsid proteins of 660 amino acids and contains three potential glycosylation sites. The ORF2 protein contains multiple immunogenic sites and neutralizing antibodies are directed against it al., .The essential region in the protein for immunogenicity is 452aa-617aa and the neutralizing epitopes have recently been shown to be conformational .ORF3 is located between the other two reading frames and encodes a small phosphoprotein of 123 amino acids. Its exact function has not been yet determined, however, multiple functions have been proposed. It is thought to interact with cellular mitogen-activated protein kinase phosphatase and other extracellular kinases, promoting cell survival through activation of intracellular signaling pathways .Moreover, the binding of the ORF3 encoded protein to host-specific proteins seems to influence the pathogenesis of HEV infections .A schematic drawing of the HEV genome is described in Figure 1 .
Read the detailed description
General aim To identify the overall and subgroup-specific HEV sero-prevalence in Israel and examine associations between HEV seropositivity and putative risk factors.
3.2 Specific aims
- To determine the sero-prevalence of Israeli healthy population.
- To quantify the sero-prevalence of HEV infections in Israeli healthy population by age, gender, ethnicity, religion.
- To present the seroprevalence in five specific groups (farmers and swine veterinaries, unexplained acute hepatitis, immunosuppressed transplant recipients, immunosuppressed HIV patients) and identify if these specific population groups are at high risk of HEV sero-prevalence.
- To identify risk factors associated with an increased risk of HEV sero-prevalence in immunosuppressed transplant patients.
- To identify risk factors associated with an increased risk of HEV sero-prevalence in farmers and swine veterinaries.
- To identify the molecular characteristic of HEV in Israel and investigate the similarities to previously published HEV sequences.
- To identify the incidence of HEV seroconversion/ infection in transplant recipients. (sero-negative pre-transplanted patients will be tested consistently for HEV Ab's and HEV RNA after transplantation)
- Conditions
- Chronic Hepatitis E
- Being tested
- questionnaires
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
questionnairesBehavioural
questionnaires , serum samples will be used
| Study group | Role | What they receive |
|---|---|---|
| subgroup-specific HEV in Israel | Other | The study will involve patient interviews using questionnaires Receives: Behavioral: questionnaires |
What is being measured
The primary outcome is the main question the study is designed to answer.
study will measure the frequency of HEV infection in immune compromised population and in subjects with unexplained elevation of liver enzymes
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Apr 2015 (estimated)
- Study startJun 2015
- Primary completionApr 2017 (estimated)
- Study completionApr 2017 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Hepatitis EStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Carmel Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Eli Zuckerman, Carmel Medical Center
- Investigators
- eli zuckerman, Principal investigator, Carmel Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02419625
- Sponsor's protocol ID
- CMC-15-0021-CTIL
- Status last verified
- Jul 2016
- First submitted
- 22 Mar 2015
- Last updated
- 21 Jul 2016
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Jul 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Epidemiology of Hepatitis E Virus Infection in Israel and Potential Risk Factors, a Multicenter, Comparative, Cross-sectional Study
- ClinicalTrials.gov ID
- NCT02419625
- Acronym / sponsor ID
- CMC-15-0021-CTIL
- Conditions
- Chronic Hepatitis E
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Carmel Medical CenterUniversity, hospital or other
- Study start
- Jun 2015
- Primary completion
- Apr 2017 (estimated)
- Study completion
- Apr 2017 (estimated)
- First posted
- 17 Apr 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Hepatitis E virus is a single-stranded positive-sense RNA virus with genome of approximately 7.2kb in length. The HEV genome is capped at the 5' end followed by a small untranslated region of 27 nucleotides and polyadenalated at the 3' end preceded by another UTR of 65 nucleotides . HEV has three open reading frames: ORF1, ORF2 and ORF3 that encode structural and non- structural proteins. ORF1 is the largest one, approximately 5,000 nt in length, located at the 5 ' end and encodes important proteins for the replication process (methyltransferase, papain-like cysteine protease, helicase, and RNA-dependent RNA polymerase). A noncoding, hypervariable region within ORF1 displays substantial genetic diversity; this region seems to modulate the efficiency of HEV replication. Notably, the differences in the genome size among different HEV strains are confined mainly to this region .ORF2 is located at the 3' end, encodes structural capsid proteins of 660 amino acids and contains three potential glycosylation sites. The ORF2 protein contains multiple immunogenic sites and neutralizing antibodies are directed against it al., .The essential region in the protein for immunogenicity is 452aa-617aa and the neutralizing epitopes have recently been shown to be conformational .ORF3 is located between the other two reading frames and encodes a small phosphoprotein of 123 amino acids. Its exact function has not been yet determined, however, multiple functions have been proposed. It is thought to interact with cellular mitogen-activated protein kinase phosphatase and other extracellular kinases, promoting cell survival through activation of intracellular signaling pathways .Moreover, the binding of the ORF3 encoded protein to host-specific proteins seems to influence the pathogenesis of HEV infections .A schematic drawing of the HEV genome is described in Figure 1 .
Detailed description
General aim To identify the overall and subgroup-specific HEV sero-prevalence in Israel and examine associations between HEV seropositivity and putative risk factors.
3.2 Specific aims
- To determine the sero-prevalence of Israeli healthy population.
- To quantify the sero-prevalence of HEV infections in Israeli healthy population by age, gender, ethnicity, religion.
- To present the seroprevalence in five specific groups (farmers and swine veterinaries, unexplained acute hepatitis, immunosuppressed transplant recipients, immunosuppressed HIV patients) and identify if these specific population groups are at high risk of HEV sero-prevalence.
- To identify risk factors associated with an increased risk of HEV sero-prevalence in immunosuppressed transplant patients.
- To identify risk factors associated with an increased risk of HEV sero-prevalence in farmers and swine veterinaries.
- To identify the molecular characteristic of HEV in Israel and investigate the similarities to previously published HEV sequences.
- To identify the incidence of HEV seroconversion/ infection in transplant recipients. (sero-negative pre-transplanted patients will be tested consistently for HEV Ab's and HEV RNA after transplantation)
Study design
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| subgroup-specific HEV in Israel | Other | Behavioral: questionnairesThe study will involve patient interviews using questionnaires |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Patients with elevated liver enzymes of unknown etiology
- Patients with acute hepatitis of unknown etiology
- Patients with chronic infection with hepatitis B , D or C.
- Immunosuppressed patients: patients with solid or haemato-oncologic malignancy or patients with chronic HIV infection.
- Patients with chronic liver disease of unknown etiology
Key exclusion criteria (3 listed)
- Participants who do not fill the above criteria
- Participants who are not willing to sign an inform consent
- Participants younger than 18 year old
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| questionnairesquestionnaires , serum samples will be used | Behavioural | subgroup-specific HEV in Israel |
Primary outcome
study will measure the frequency of HEV infection in immune compromised population and in subjects with unexplained elevation of liver enzymes
Time frame: 2 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jul 2016.
Related trials for Chronic Hepatitis E
RecruitingPhase 2
Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions
Hepatitis B, Chronic
RecruitingPhase 2
Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region
Hepatitis B, Chronic
RecruitingPhase 4
Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients
Hepatitis B, Chronic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
eli zuckerman principal investigator
Carmel Medical Center
Questions about this trial
What is this clinical trial studying?
A study testing questionnaires in people with Chronic Hepatitis E, run by Carmel Medical Center.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 21 Jul 2016. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
study will measure the frequency of HEV infection in immune compromised population and in subjects with unexplained elevation of liver enzymes (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jul 2016.